RHEUMATOLOGY, ALLERGY & IMMUNOLOGY GRAND ROUNDS

*Presented by*

Section of Rheumatology, Allergy & Immunology

“Rheumatologists and Checkpoint Inhibitors”

**Yuliya Afinogenova, MD**

Clinical Fellow, Section of Rheumatology, Allergy & Immunology

**Date: Wednesday, June 3, 2020 Time: 8:00-9:00 am**

**Via Zoom -** <https://zoom.us/j/93513068158>

**Via phone – Dial 203-432-9666 Meeting ID: 935 1306 8158**

CME: To record your attendance to this activity,
text the Activity Code, 14996 to 203-442-9435 from 7:45am-9:15am

**Course Director/Host: Fotios Koumpouras, MD**

***There is no corporate support for this activity***

This course will fulfill the licensure requirement set forth by the State of Connecticut

**ACCREDITATION**

The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

**TARGET AUDIENCE**

Department faculty, attending physicians, subspecialty fellows, community physicians, resident house staff, physician assistants and medical students.

**NEEDS ASSESSMENT**

With the increasing use of checkpoint inhibitor therapy for malignancies, rheumatologists are helping to manage immune-related adverse events. It is important to be aware of these events as they they can clinically differ from classical rheumatic diseases.  Dr. Afinogenova will explain what is known about the mechanism, diagnosis, and treatment of checkpoint inhibitor-associated immune related adverse events, and discuss experiences to date at Yale.

Further reading: Postow MA et al. Immune-Related adverse events associated with immune checkpoint blockade. NEJM 2018

**LEARNING OBJECTIVES**

At the conclusion of this activity, participants will be able to:

1. Understand the mechanism of action of checkpoint inhibitors and source of immune related adverse events
2. Understand the different types of rheumatic immune related adverse events, diagnostic dilemmas, and treatment options
3. Learn about Yale rheumatology experience with checkpoint inhibitors

**DESIGNATION STATEMENT**

The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

**FACULTY DISCLOSURES**

*Speaker:* Yuliya Afinogenova, MD – NONE

*Course Director:* Fotios Koumpouras, MD- Celgene (honorarium), Aurora (research grant), EMD, ULB, GSK (research grant)

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.